Management of septic shock: new approaches.
Baumgartner
J D
JD
Eggimann
P
P
Glauser
M P
MP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004926:Escherichia coli / Q000276:immunology; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008070:Lipopolysaccharides / Q000276:immunology; D009270:Naloxone / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D012772:Shock, Septic / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D009270:Naloxone; D010431:Pentoxifylline